Latest News Archive

Please select Category, Year, and then Month to display items

2024 Elections: What the future holds after 29 May

02 May 2024 | Story Dr Nitha Ramnath | Photo right

2024 UFS Thought-Leader Webinar Series

PRESENTS

a webinar titled

2024 Elections: Promises, Perils, and Delivery: What the Future Holds After 29 May 2024?

The University of the Free State (UFS) is pleased to present its first webinar for the year, titled 2024 Elections: Promises, Perils, and Delivery: What the Future Holds After 29 May 2024? – which is part of the 2024 Thought-Leader Webinar Series. As a public higher-education institution in South Africa with a responsibility to contribute to public discourse, the university will be presenting the webinar as part of the UFS Thought-Leader Series, which is in its sixth consecutive year. The aim of the webinar series is to discuss issues facing South Africa by engaging experts at the university and in South Africa.

Webinar presented on 23 May 2024

On 29 May 2024, South Africans will go to the polls. This election is considered by South Africans as significant and much needed since the end of apartheid in 1994. South Africa is plagued by record power cuts, poor service delivery, and high levels of unemployment, with drastic effects on businesses and the local economy. Coinciding with the celebration of 30 years of freedom and democracy, this seventh democratic election is a turning point for South Africa to determine the desired future for all South Africans.

Date: Thursday 23 May 2024

Time: 12:30-14:00

RSVP: Click to view document HERE no later than 22 May 2024.

Some of the topics discussed by leading experts in 2023 included, among others, Threats to South Africa’s stability and security challenges; The need for a global and regional plan / approach to respond to the consequences of the Russia-Ukraine war; and Student protest action, politics, and higher education.

Facilitator:

Prof Francis Petersen

Vice-Chancellor and Principal, UFS

Panellists:

Prof Bonang Mohale

Chancellor, UFS

Dr Ebrahim Harvey

Political writer and commentator

Bios of speakers:

Prof Bonang Mohale

Prof Bonang Mohale is the Chancellor of the University of the Free State, former President of Business Unity South Africa (BUSA), Professor of Practice in the Johannesburg Business School (JBS) College of Business and Economics, and Chairman of two listed entities – the Bidvest Group Limited and ArcelorMittal, as well as SBV Services and Swiss Re Corporate Solutions! He is a member of the Community of Chairpersons (CoC) of the World Economic Forum and author of two best-selling books, Lift As You Rise and Behold The Turtle! He has been included in the Reputation Poll International’s (RPI) 2023 list of the ‘100 Most Reputable Africans’. The selection criteria are integrity, reputation, transparency, visibility, and impact. He is the recipient of the 2023 ME-Vision Academy’s ‘Exclusive Recognition in Successful Leadership’ Award for consistently leading self successfully, consistently leading people successfully, successfully leading as a senior executive and CEO, successfully leading society in various impactful roles, and his contribution to mentoring and inspiring future successful leaders.

Dr Ebrahim Harvey

Dr Ebrahim Harvey is a political writer, analyst, commentator, former Cosatu trade unionist, and Mail & Guardian columnist. He is currently a News24 columnist. He also wrote the authorised biography of former president, Kgalema Motlanthe (2012), and The Great Pretenders: Race and Class under ANC Rule (2021), which won the 2022 SA Literary Award for Non-Fiction. He holds a master’s degree in Public and Development Management and a PhD degree in Sociology, both from the University of the Witwatersrand.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept